Femasys Inc. to Showcase FemCerv at the Annual Meeting for the American Society for Colposcopy and Cervical Pathology
May 01, 2023 16:05 ET
|
Femasys Inc.
ATLANTA, May 01, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include...
Femasys Announces $3.9 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 19, 2023 08:00 ET
|
Femasys Inc.
ATLANTA, April 19, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs by developing a suite of products and product candidates that include...
Femasys’ FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada
April 18, 2023 08:00 ET
|
Femasys Inc.
- FemaSeed® is the first-ever, first-line approach designed to deliver sperm directly where contraception occurs - ATLANTA, April 18, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a...
Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update
March 30, 2023 08:00 ET
|
Femasys Inc.
- 2022 was a landmark year for women in the U.S. due to the overturn of Roe v. Wade which underscored the importance of potential reproductive health options like Femasys’ FemBloc® for permanent birth...
Femasys Inc. to Participate in “The Post-Roe Fertility Journey” Panel Discussion at SXSW 2023
March 09, 2023 08:00 ET
|
Femasys Inc.
ATLANTA, March 09, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include...
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update
November 10, 2022 08:44 ET
|
Femasys Inc.
--FemaSeed® de novo trial enrollment accelerates with strategic trial design update to focus on male factor infertility-- --Company remains on track to file an Investigational Device Exemption (IDE)...
Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control
October 06, 2022 08:01 ET
|
Femasys Inc.
ATLANTA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally...
Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team
September 29, 2022 08:00 ET
|
Femasys Inc.
- FemCerv® is the first endocervical tissue sampler designed to improve tissue quality and quantity that is expected to be an improvement over the existing standard of care - - Company expands...
Femasys Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 01, 2022 16:05 ET
|
Femasys Inc.
ATLANTA, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include...
Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update
August 10, 2022 16:05 ET
|
Femasys Inc.
Continued focus and progress with FemaSeed® and FemBloc® biomedical product candidates in developmentFemCerv® and FemCath™ commercial availability expected by year-end ATLANTA, Aug. 10, 2022 ...